European Journal of Molecular & Clinical Medicine
ISSN 2515-8260 Volume 07, Issue 11 , 2020

Preparation And Uses Of Antipsychotic Key Drug Substances Via Non-Infringing, Scalable Processes

Brahma Srinivasa Rao Aala[1] , Dr. H. L. Saxena[2]

[1] Research Scholar , [2]Research Supervisor

Department of Chemistry, Himalayan University, Itanagar, Arunachal Pradesh, INDIA.

Abstract

In schizophrenia-spectrum illnesses, antipsychotic medication is beneficial for symptomatic therapy. Compared to dose reduction or discontinuation, maintenance of antipsychotic treatment is related to lower recurrence rates and symptom severity after symptom remission. In this research, we will explain how antipsychotic medications can have scalable and non-violent methods for synthesizing major antipsychotic drug compounds such as olanzapine, aripiprazole, quetiapine, and ziprasidone, which have oxidant & antioxidant properties but do not go any further. A single mode of action for many prescribed antipsychotics will be demonstrated for the first time to have no effect on lipid peroxidation.

KEYWORDS: Antipsychotic, FTO, Drug, Scalable Processes, Non-Infringing

I. INTRODUCTION

Antipsychotics, also called neuroleptics [1, 2], are a form of psychotropic medications for treating psychosis, most typically observed in schizophrenia but can also occur in a range of other psychotic disorders. They're also the cornerstone of bipolar illness treatment, alongside mood stabilizers [3]. According to recent studies, the use of any antipsychotic results in reduced brain tissue volumes, which is dose and duration dependant [4]. This impact has also been confirmed by a review of the research [5]. Antipsychotic medications can produce many adverse reactions, particularly impotence, involuntary movement irregularities, gaining weight, gynecomastia, and the development of the metabolic syndrome.

Typical antipsychotics are 1st generation antipsychotics that are "Dopamine Receptor Antagonists (DRA)." They are as follows:

- Butyrophenones (haloperidol)
- Phenothiazines (mesoridazine, trifluoperazine, prochlorperazine, perphenazine, triflupromazine, acetophenazine)
- Dibenzoxazepines (loxapine)

- Thioxanthenes (chlorprothixene, thiothixene)
- Diphenylbutylpiperidines (pimozide)
- Dihydroindoles (molindone)

These "serotonin-dopamine antagonists" are also referred to as "atypical antipsychotics," which are antipsychotics of the 2nd generation. In 2016, the Food and Drug Administration (FDA) authorised a total of 12 atypical antipsychotic medications which are as follows:

- Clozapine
- Risperidone
- Quetiapine
- Olanzapine
- Aripiprazole
- Ziprasidone
- Asenapine
- Paliperidone
- Iloperidone
- Lurasidone
- Brexpiprazole
- Cariprazine

Nowadays, strategic business techniques, like "non-infringement or Freedom of Operation (FTO)" perspective, are increasingly being adopted by organisations in vital areas like product launching, mergers & acquisitions, contract manufacturing, and even the formulation of R&D plans. Non-infringement, or FTO, views are legal interpretations given by a patent lawyer with the goal of protecting the client from infringing on the patents of others. A lawyer's judgment on whether the client's product, method, or technology is acceptable can be found in these legal opinion documents. A lawyer must conduct considerable research into relevant existing patents before issuing an FTO opinion, whereas a non-infringement view is submitted on one or more pertinent patents that have already been found. According to the outcomes of prospective research, pharmaceutical intervention associated with changes in energy intake & expenditure may be able to minimize the genetic susceptibility of the FTO genotype.

This research exemplifies the purpose of developing alternative methods for manufacturing atypical antipsychotic drugs, including the detection, characterization, and synthesis of their associated substances and their effect. The goal of this study is to develop a systematic method for making the critical compounds that are easy, scalable, and economical.

II. PROBLEM STATEMENT

This study is focused on the scalable preparation techniques for olanzapine, aripiprazole, quetiapine, and ziprasidone, along with their usage under the API standard of antipsychotic. The research entitled, **“Preparation and uses of antipsychotic Key Drug Substances via Non-Infringing, Scalable Processes.”**

III. OBJECTIVES OF THE STUDY

This research has the following objectives:

- To conduct an investigation on non-infringing cost-effective & scalable techniques for the synthesis of essential ingredients for antipsychotic drugs.
- To investigate the efficacy of an antipsychotic important drug in the treatment of behavioural disease.

IV. HYPOTHESIS

H1: Non-Infringing scalable processes for preparation of olanzapine, aripiprazole, quetiapine, and ziprasidone are cost-effective methods.
H2: The Antipsychotic key drugs are effective in treating behavioural illness.

V. NEED OF THE STUDY

The purpose of the present research aims to explain "the preparation of atypical key antipsychotic substances. Since most of the techniques for these pharmaceutical compounds have been secured by patents valid throughout the world, businesses such as Innovator Pharma, etc., do have monopolistic patent rights. As a result, identifying, quantifying, and controlling flaws in pharmaceutical substances and pharmaceutical products is a crucial aspect of developing medications to secure marketing authorizations.

In order to better understand how to synthesize and use selectively atypical antipsychotics, the suggested research will focus substantially on new synthetic techniques. These alternative synthetic processes have the advantage of having an early launch opportunity in some countries where many methods of these drugs have been protected through valid patents by innovative companies.

VI. RESEARCH METHODOLOGY

The following research study summarises alternative, non-infringing, and scalable techniques for manufacturing atypical antipsychotic main drug ingredients like olanzapine, aripiprazole, quetiapine, and ziprasidone to API standards.

Chemical synthesis processes are used in this study. The long-term objective of basic research in synthesizing is to demonstrate the ability to synthesize all of the compounds in a controlled laboratory environment and investigate the properties of transition that are achievable within the limits of the laws of the universe.

(a) Preparation of Olanzapine

Olanzapine is classed as a thienobenzodiazepine, despite being chemically close to clozapine, a dibenzodiazepine medication. Because of its structural resemblance to the medication clozapine, which also pertains to the dibenzodiazepine class, olanzapine is labelled as a thienobenzodiazepine rather than a dibenzodiazepine. Some atypical antipsychotics have a reduced affinity for histamine, alpha, muscarinic, and cholinergic adrenergic receptors. This

medicine may have an antipsychotic effect due to the serotonin receptor antagonism that it causes.

(b) Preparation of Aripiprazole

Aripiprazole doesn't have a significant affinity for cholinergic muscarinic receptors, although it does have a modest affinity for histamine and α-adrenergic receptors for serotonin transporter. The synthesis of Aripiprazole will also take us down a different route, primarily involving the Beckmann rearrangement circumstances that result in the formation of a carbostyryl residue.

(c)Preparation of Quetiapine

The 10 ml methanol & chloroform combination is dissolute in Quetiapine emulsifier, fumarate, as well as solid lipid (egg lecitin) (1:1). It was heated to 5 degrees Celsius over the melting point of the inserted lipid sheet to bring it together. After dissolving the stabilizer in distilled water (1.5 percent W/V), the stabiliser (poloxamer 188) was heated to almost the same temp. as the fuel procedure. Phases were mixed together in a homogenizer for 5 minutes using hot aqueous phase and the homogenizer (DIAX 900 Heidolph, Germany) (12000 rpm). In order to sonicate the water emulsion, a sonic sensor (12t) (Vibracell Sonics, USA) was applied for 20 minutes. After cooling to room temp, SLNs loaded with Quetiapines fumarates were produced.

(d) Preparation of Ziprasidone

Three distinct procedures for making Ziprasidone, an atypical antipsychotic medication, have been developed in order to address the concerns that were discovered during the previous synthetic approaches to the medicine. As part of the regulatory standards, the defined content of the related chemicals specified in the pharmacopoeia should be kept in order to be considered valid. As a result, additional techniques involving simple reaction situations will be offered to create the three related chemicals mentioned.

VII. RESULTS AND DISCUSSION

Heat homogenization & ultrasonication were used to make quetiapine fumarate-loaded SLNs with 3 distinct lipids. There is some evidence that SLN dispersions can be caused by using egg lecithin & poloxamer as surfactants. This formulation of SLN with Dynasan 118 was developed dependent on the particle size (PEDI), zeta potential, trapping efficacy, and release of drug properties. In-vitro bioavailability tests have shown a 3.71-fold increase in the relative bioavailability enhancement over the reference suspension. Quetiapine fumarate can thus improve oral bioavailability when manufactured as SLN. Induction of ketamine generated symptoms in rats that were similar to schizophrenia. In alleviating ketamine-induced schizophrenia symptoms in rats, QF-loaded nanoparticles (QFSLN) are more effective than QuF. Both QF and QF SLN have dose-dependent effects. Thus, QF nanoparticles were more soluble and more effective for an antipsychotically modified medication. The use of nanoparticles loaded with QF can benefit schizophrenia and other associated conditions. To improve oral bioavailability, Narala and Veerabrahma [6] combined quetiapine fumarate using

solid lipid nanoparticles (SLN). After the first formation of clozapine was reported by Hunziker et al. in 1967 [7], several analogous syntheses were recorded [8-10]. Development of a simple and novel process for the preparation of Aripiprazole has been conveyed in refs. [11, 12]. In accordance with the procedures described in ref. [13], the quetiapine fumarate-loaded SLNs were produced using a process that included heat homogenization and ultrasonication. Risperidone preparation was transformed by Meenakshisunderam et al. [14], who demonstrated a cost-effective approach.



Figure 1.0: SLNs loaded with Quetiapine Fumarate with 3 lipids - Dynasan-114, Dynasan-118, & Imwitor-900P

VIII. IMPACT OF ANTIPSYCHOTIC DRUGS IN HUMAN PLASMA

The possibility of the chosen "atypical antipsychotic drugs" as well as haloperidol to impact lipid peroxidation in human plasma demonstrated as the TBARS level differs in the final levels relating to their effective therapeutic concentrations in the patient's plasma after the therapies of the acute illness of schizophrenia.



Figure 1.1: Atypical antipsychotics (DAA; final concentrations corresponding to effective therapeutic dosages used for the treatment of schizophrenia) have been shown to have beneficial impacts on lipid oxidation, as evaluated by TBARS level in human plasma after a 24 hr. incubation period with the drug (percent), where the TBARS level in the control plasma (without the drug) was 100 percent.

At the TBARS level, the impacts of two dosage treatment (lower and higher) with the medications under investigation were evaluated. Aripiprazole had no significant effect on the amount of a marker of plasma oxidative stress that had been tested. Its effect is dose-dependent. At a low dosage, aripiprazole generated minor lipid peroxidation in the plasma, showing prooxidative qualities (Figure 1.2a), whereas aripiprazole at a greater level, like clozapine, had a minimal antioxidant impact with the amount of TBARS in plasma (Figure 1.2b). Clozapine, perhaps at a smaller concentration, exhibited prooxidative effects (Figure 1.2a). Quetiapine as well as olanzapine, particularly at lower concentrations, lowered the TBARS level relative to the control by roughly 14 percent and 7 percent (Figure 1.1). Clozapine was found to have decreasing characteristics when administered at a greater dose. Because of their oxidative qualities, risperidone, ziprasidone, and haloperidol, particularly at higher levels, induced a rise in the content of TBARS in human plasma by roughly 13 percent, 28 percent, and 14 percent, respectively (Figure 1.1).



Figure 1.2: (a) The effects of atypical antipsychotic drugs (DAA) at lower concentrations of thiobarbituric acid reactive substances (TBARS) in plasma after 24-hour incubation (post hoc analysis [LSD test]). (b) The effects of ADF at higher concentrations of plasma TBARS after 24 hours of incubation (post hoc analysis [LSD test])



Figure 1.3: Comparing the impacts of aripiprazole & other antipsychotics (at a greater doses) on the amount of plasma lipid peroxidation (post hoc analysis [LSD test]). The variations in the concentration of thiobarbituric acid reactive substances (TBARS); rise, reduction) after 24 hour incubation of human plasma with antipsychotic medication. Aripiprazole (ARI); clozapine (CLO); Haloperidol (HAL); olanzapine (OLA); Quetiapine (QUE); Risperidone (RIS); ziprasidone (ZIP).

The analysis of ANOVA II test revealed that the differences in the TBARS levels significantly based on the studied drug ($P = 3.78 \times 10^{-7}$). In the post hoc analysis (LSD test), significant differences in the TBARS level between the investigated AAD were found (Tables 1 and 2).

Table 1.1 Statistically significant differences for Figure 1.2a

Drug:	QUE vs CLO $P = 1.2 \times 10^{-3}$	QUE vs ARI $P = 1.6 \times 10^{-2}$	QUE vs RIS $P = 8.7 \times 10^{-4}$	QUE vs ZIP $P = 1.1 \times 10^{-5}$
Drug:	OLA vs RIS $P = 3.8 \times 10^{-2}$	OLA vs ZIP $P = 3.4 \times 10^{-2}$	OLA vs ZIP $P = 1.1 \times 10^{-3}$	
Drug:	ARI vs ZIP $P = 2.6 \times 10^{-2}$			

ARI, aripiprazole; CLO, clozapine; HAL, haloperidol; OLA, olanzapine; QUE, quetiapine; RIS, risperidone; ZIP, ziprasidone.

Table 1.2 Statistically significant differences for Figure 1.2b

Drug:	ZIP vs QUE $P = 1.0 \times 10^{-7}$	ZIP vs OLA $P = 2.0 \times 10^{-6}$	ZIP vs CLO $P = 1.0 \times 10^{-6}$	ZIP vs ARI $P = 3.0 \times 10^{-6}$	ZIP vs RIS $P = 5.9 \times 10^{-4}$
Drug:	QUE vs RIS $P = 5.7 \times 10^{-4}$				

ARI, aripiprazole; CLO, clozapine; OLA, olanzapine; QUE, quetiapine; RIS, risperidone; ZIP, ziprasidone.

IX. APPLICATIONS OF THESE DRUGS

Drug technology underwent phenomenal development in the first two decades of the 20th century. New knowledge and sometimes uncertainty have contributed in discovering new medicines, with the therapeutically effective substances being found over the years, rendering chemotherapy an essential aspect of medical practice. Meanwhile, several antibiotics [15], vaccines [16], cardiovascular medications, antihypertensive [17], anti-coagulants, anti-inflammatory drugs, relaxants, stimulants, depressants, antipsychotics [18], analgesics, opioids, barbiturates [19], vitamins, and nutritional minerals have been developed and are on the path to enhance their medicinal effectiveness.

Anxiolytics, such as antipsychotics, are the first-line evidence-based treatment for schizophrenia and other major psychiatric illnesses. As a result, these antipsychotics are now approved for the therapy of bipolar disorder and other conditions that are difficult to treat. On the other hand, such therapies are conducted off-label to patients suffering from situations like borderline personality abnormality, obsessional-compulsive impairment, anorexia nervosa, anxiousness, delirium, as well as numerous dementia symptoms and signs, such as Alzheimer's disease, and other mental health issues.

Nonetheless, because these therapies are related to various undesirable adverse reactions, some of which are clinically serious and all of which affect patients' perspectives towards treatment, their efficacy is compromised. To exemplify this, specialists and suggestions commonly provide antipsychotic therapies depending on adverse reactions profiles which vary considerably from one another, instead of on effectiveness that is considered equivalent [20, 21].

X. RISKS & ADVERSE EFFECTS OF ANTIPSYCHOTIC DRUGS

Negative consequences of antipsychotic treatments vary from reasonably slight complications of tolerability (e.g. moderate sedation or dry mouth) to very unpleasant (e.g. constipation, akathisia, sexual dysfunction) to debilitating (e.g. acute dystonia) to disfiguring (e.g. weight gain, tardive dyskinesia) and life-threatening (e.g. acute dystonia) (e.g., myocarditis, agranulocytosis). Any adverse reactions (e.g., elevated prolactin or serum lipid levels) have minimal short-term health effects, but can include a long-term risk of medical complications.

There is a particular side effect profile for an antipsychotic drug, which affects people differently. Several side consequences are specific to clozapine: epilepsy, neutropenia, sialorrhea. Gaining weight is not peculiar to newer drugs, nor is it found in all newer drugs. Likewise, akathisia & Parkinsonism are common side effects of both newer and older treatments. Older antipsychotic medications are rarely used as a first-line treatment for bipolar illness, and their efficacy in treating depressed symptoms or preventing episodes has been questioned. They may, however, be helpful if a person experiences bothersome side effects or does not respond to the newer medications. These medications may cause tardive dyskinesia, a movement disease characterized by repetitive, involuntary lip-smacking, projecting the tongue, and grimacing. This side effect is also possible with newer atypical antipsychotics, but the risk is lower than older conventional antipsychotics.

XI. CONCLUSION

Behavioural symptoms are an element of dementia's complexity, linked to a poorer cognitive outcome. Treating them can be difficult, especially when dealing with complex and weak patients. When contrasted with the conventional antipsychotic treatment of the prior generation, newer targeted therapies (APIs) like antipsychotics play a significant part in people's everyday lives. Quetiapine, olanzapine, ziprasidone, and aripiprazole are atypical antipsychotics that have gained particular attention as medications. This research has involved a thorough investigation of novel potential synthetic techniques for selectively atypical antipsychotic APIs (active pharmaceutical ingredients). Additionally, this research aims to discover, characterize, and synthesize any related compounds produced during the production of these therapeutic molecules.

REFERENCES

1. Finkel R., Clark M. A., Cubeddu L. X. 2009. Pharmacology. Lippincott Williams & Wilkins.
2. Lally J., Maccabe J. H. 2015. British Medical Bulletin 114 (1): 169–79.
3. Grande I., Berk M, Birmaher B, Vieta E. 2016. Lancet 387 (10027): 1561–72.
4. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. 2011. Archives of General Psychiatry 68 (2): 128–37.
5. Moncrieff J, Leo J. 2010. Psychological Medicine 40 (9): 1409–22.
6. Narala A., Veerabrahma K., Journal of Pharmaceutics, 2013 (265741):1-7.
7. Hunziker F., Fischer E., Schmitz J. 1967. Helv. Chim. Acta 50 (6): 1588–1599.

8. Paulis T., Davis D., Smith H, Malarek D., Liebman A. 1988. Journal of Lobelled Compowds and Radio pharmaceuricaL 25 (9), 1027–1033.
9. Michael J., Edward J., 1993. J. Anal. Prof. Drug Substances Excipients 22, 145–184.
10. Paulis, T., Betts C.R., Smith H.E., Mobley P.L., Manier D.H., Sulser F., 1981. J. Med. Chem. 24 (9): 1021–1026.
11. Chander T., Satyanarayana B., Kumar N., Reddy P., & Anjaneyulu Y. 2007. Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry 37 (24): 4337-4341.
12. Satyanarayana B., Sumalatha Y., Kumar S.S., Venkatraman S., Reddy G.M., Reddy P.P. (2005). Heterocyclic Communications. 11 (6): 485-490.
13. R. H. Müller, K. Mäder, and S. Gohla, "Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art," European Journal of Pharmaceutics and Biopharmaceutics, vol. 50, no. 1, pp. 161–177, 2000
14. Meenakshisunderam S., Rama S., Chetan P. 2004. https://patentimages.storage.googleapis.com/e8/d1/10/c8c7e76a569b33/WO2004009591A1.pdf
15. Foster W., Raoult, A. 1974. The Journal of the Royal College of General Practitioners 24 (149): 889-94.
16. Stern A. M., Markel H. 2005. Health affairs. 24 (3): 611-21.
17. Kostis J. B. 2008. New England Journal of Medicines. 431.
18. Horacek H., Bubenikova V., Kopacek, M. 2006. CNS Drugs. 20: 389.
19. Sneader W. 2005. Drug Discovery- A History. John Wiley and Sons, Ltd.
20. Goff D. C. 2014. The Journal of the American Medical Association. 311:1973-4.
21. International College of Neuropsychopharmacology. CINP schizophrenia guidelines. http://cinp.org/cinp-schizophrenia-guidelines/.